Literature DB >> 353991

Approaches to the treatment of acute leukemia and lymphoma in adults.

G P Bodey, V Rodriguez.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 353991

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


× No keyword cloud information.
  8 in total

1.  Individual nuclear uptake patterns for adriamycin and daunomycin in human leukemia and lymphoma cells.

Authors:  S Seeber; H Loth
Journal:  Blut       Date:  1981-06

2.  Intensification of remission induction therapy for acute nonlymphocytic leukemia (ANLL). I. Response and toxicity in four different regimens.

Authors:  T Büchner; D Urbanitz; W Hiddemann; D Kamanabroo; R Meister; L Balleisen; U Delvos; E M Lagrèze; U Schmitz-Huebner; H Schulte; J van de Loo
Journal:  Blut       Date:  1979-08

3.  Adriamycin and cytosine arabinoside contribute equally to prediction of response in acute myelocytic leukemia with improved confidence level.

Authors:  M G Lihou; P J Smith
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  [Long-term survival of adults with acute leukemia [author's transl)].

Authors:  H C Benöhr; G Reu; K Wilms; H D Waller
Journal:  Blut       Date:  1980-06

5.  New approaches to the management of patients with non-Hodgkin's lymphoma of high-grade pathology. First Gordon Hamilton-Fairley memorial lecture.

Authors:  D Crowther
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640

6.  Quantitation of chemosensitivity in acute myelocytic leukaemia.

Authors:  M G Lihou; P J Smith
Journal:  Br J Cancer       Date:  1983-10       Impact factor: 7.640

7.  Fluorescence polarization with FDA in leukaemic cells: a clear difference between myelogenous and lymphocytic origins.

Authors:  H Tsuda; H Maeda; S Kishimoto
Journal:  Br J Cancer       Date:  1981-06       Impact factor: 7.640

8.  Chemotherapy of lung cancer.

Authors:  R J Papac
Journal:  Yale J Biol Med       Date:  1981 Jul-Aug
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.